Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PET guidance for radiation therapy improves prostate cancer outcomes

Key clinical point: Adding molecular imaging to conventional imaging to guide postprostatectomy radiation therapy improves efficacy.

Major finding: The 3-year failure-free survival rate was 63.0% with conventional imaging guidance alone and 75.5% with added fluciclovine PET imaging guidance (P = .033).

Study details: A phase 2/3, randomized trial of 165 men with prostate cancer undergoing postprostatectomy radiation therapy who had detectable prostate-specific antigen but negative conventional imaging results.

Disclosures: The EMPIRE-1 trial was supported by the National Institutes of Health. Dr. Jani disclosed advisory board service for Blue Earth Diagnostics.


Jani A et al. ASTRO 2020, Abstract LBA1.